An estimated 25% of people carry a genetic variant (HLA-DR haplotype) that makes them more likely to have this kind of extreme response
Whether investigating collagen-related pathways, skin appearance research, hair follicle studies, or broader regenerative science applications, GHK-CU remains one of the most established peptides in this category
Company Profile Shijiazhuang ASA technology Co., Ltd
Potential Side Effects and Limited Human Data While preclinical studies have not shown significant toxicity at standard doses, the research in humans is still in its early stages
Patients should be reviewed 812 weeks after commencing treatment to assess: Symptomatic improvement, particularly resolution of fatigue and neurological symptoms Haematological response (normalisation of haemoglobin and mean cell volume) Reticulocyte count typically rises within one week, indicating bone marrow response Repeat serum B12 testing is generally not useful after starting parenteral therapy, as levels remain elevated for months